Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
Future Oncol
; 14(3): 223-228, 2018 02.
Article
em En
| MEDLINE
| ID: mdl-29318901
ABSTRACT
AIM:
Patients with advanced gastric cancer have a relatively poor prognosis with few therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to highlight the potential for prolonged responses in patients with HER-2-positive disease. Patients, materials &methods:
We analyzed the data of patients diagnosed with HER-2-positive-advanced gastric cancer who progressed on trastuzumab-based combination therapy and subsequently received second-line therapy consisting of ramucirumab in combination with paclitaxel.RESULTS:
Most patients had a stable disease after ramucirumab-based therapy (50%, 5/10), median duration to disease control was 8 months.CONCLUSION:
The prolonged duration of response that we observed indicates that an interaction between the EGF pathway and the angiogenesis pathway requires further clinical investigations.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Neoplasias Esofágicas
/
Adenocarcinoma
/
Junção Esofagogástrica
/
Antineoplásicos Imunológicos
/
Anticorpos Monoclonais
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Canadá